The Wistar Institute of Anatomy and Biology was founded in 1892 at its current site to operate as an independent research entity dedicated to the maintenance and enhancement of its anatomical collection and to """"""""the conduct of any other work for the increase of scientific knowledge."""""""" Over its history, The Wistar Institute has emerged as one of the nation's leading private basic research institutions. In recognition of its contributions in cancer research, the Institute received a Cancer Center Support (CCSG) and was designated by the National Cancer Institute (NCI) as a federally approved Cancer Center in 1972, specializing in basic research. In 1976 the NCI funded the addition of a Cancer Wing to the original Main Building. In 2002 Dr. Russel Kaufman was appointed Director and CEO of The Wistar Institute Cancer Center (Cancer Center). Following his arrival, Dr. Kaufman has led a restructuring of the Research Programs and an extensive review of the Shared Resources. Research at the Institute is organized into three programs: Gene Expression and Regulation; Cellular and Molecular Oncogenesis; and Immunology. Investigators are recognized for their leading contribution in gene regulation and chramatin modification, melanoma research, vaccine development, and translational research. The goals of the current CCSG application are to further expand on our success in these areas by recruiting new faculty to the Institute and by the Institute and by Providing an environment and resource to promote the success of the members of the Cancer Center. The Cancer Center will emphasize the study of macromolecular transcriptional complexs, mouse models of human cancer, organotypic model systems, antigen recognition and processing, immune cell trafficking, stem cell development, and systems biology. These areas of investigation will complement and expand existing areas of excellence and provide novel insights into the biology of cancer, as well as targets for cancer therapies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA010815-36S1
Application #
6894135
Study Section
Subcommittee G - Education (NCI)
Program Officer
Rosenfeld, Bobby
Project Start
1978-09-01
Project End
2008-02-29
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
36
Fiscal Year
2004
Total Cost
$123,789
Indirect Cost
Name
Wistar Institute
Department
Type
DUNS #
075524595
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5:
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Duperret, Elizabeth K; Trautz, Aspen; Stoltz, Regina et al. (2018) Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti-CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo. Cancer Res 78:6363-6370
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Kugel 3rd, Curtis H; Douglass, Stephen M; Webster, Marie R et al. (2018) Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clin Cancer Res 24:5347-5356
Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072
Bhattacharjee, Souvik; Coppens, Isabelle; Mbengue, Alassane et al. (2018) Remodeling of the malaria parasite and host human red cell by vesicle amplification that induces artemisinin resistance. Blood 131:1234-1247
Fukumoto, Takeshi; Park, Pyoung Hwa; Wu, Shuai et al. (2018) Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Rep 22:3393-3400
Thangavel, Chellappagounder; Boopathi, Ettickan; Liu, Yi et al. (2018) Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer. Clin Cancer Res 24:1402-1414

Showing the most recent 10 out of 741 publications